Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Other Accumulated Expenses (2023 - 2025)

Kura Oncology (KURA) has disclosed Other Accumulated Expenses for 3 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 25.17% to $3.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.4 million, a 25.17% increase, with the full-year FY2025 number at $3.4 million, up 25.17% from a year prior.
  • Other Accumulated Expenses was $3.4 million for Q4 2025 at Kura Oncology, down from $6.3 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $6.3 million in Q3 2025 to a low of $1.3 million in Q4 2023.
  • A 3-year average of $3.1 million and a median of $2.7 million in 2024 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: grew 20.21% in 2024, then surged 154.21% in 2025.
  • Kura Oncology's Other Accumulated Expenses stood at $1.3 million in 2023, then soared by 108.14% to $2.7 million in 2024, then grew by 25.17% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Other Accumulated Expenses are $3.4 million (Q4 2025), $6.3 million (Q3 2025), and $3.5 million (Q1 2025).